Company · CIK 0001160308 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Savara Inc · SVRA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 FForm 4 → | Sep 25, 7:01 pm EDT | Braden C. ParkerChief Commercial Officer | 29,323 | $5.07 | $148,668 | 75,677 | — | |
| Jul 15, 2026 AForm 4 → | Jul 24, 6:24 pm EDT | Robert Matthew LutzChief Fin. & Operating Officer | 35,000 | — | — | 328,977 | — | late |
| Jun 22, 2026 SForm 4 → | Jun 22, 8:18 pm EDT | David L LowranceChief Financial Officer | 394,528 | $5.68 | $2,241,432 | 536,032 | −42.4% | |
| Jun 22, 2026 FMForm 4 → | Jun 22, 8:18 pm EDT | David L LowranceChief Financial Officer | 765,846 | $2.67 | $2,042,240 | 930,560 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 AForm 4 → | Jul 24, 6:24 pm EDT | Robert Matthew LutzChief Fin. & Operating Officer | 70,000 | — | — | 70,000 | — | late |
| Jun 22, 2026 MForm 4 → | Jun 22, 8:18 pm EDT | David L LowranceChief Financial Officer | 580,187 | — | — | 187,500 | — |